[HTML][HTML] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
S Cang, C Iragavarapu, J Savooji, Y Song… - Journal of hematology & …, 2015 - Springer
S Cang, C Iragavarapu, J Savooji, Y Song, D Liu
Journal of hematology & oncology, 2015•SpringerWith the advent of new agents targeting CD20, Bruton's tyrosine kinase, and
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist
than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is
a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199
(venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for
relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical …
phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist
than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is
a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199
(venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for
relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical …
Abstract
With the advent of new agents targeting CD20, Bruton’s tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 (venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins.
Springer